Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2006

01-12-2006 | Original Article

Anti-Inflammatory Effect of Bioflora Probiotic Administered Orally or Subcutaneously with Live or Dead Bacteria

Authors: OM Laudanno, L Vasconcelos, J Catalana, JA Cesolari

Published in: Digestive Diseases and Sciences | Issue 12/2006

Login to get access

Abstract

The anti-inflammatory effect of Bioflora probiotic administered orally or subcutaneously with viable or nonviable bacteria was analyzed in two experimental models of randomly selected female Wistar rats. The use of indomethacin at a dose of 50 mg/kg was associated with gastric necrotic lesions and multiple erosions of the small intestine, with marked mucosal neutrophil infiltrate measured by myeloperoxidase (MPO). Probiotics prevented both gastrointestinal lesions and neutrophil infiltrate (p < 0.001). In the model of carrageenin-induced plantar edema in the rat, the oral or subcutaneous administration of Bioflora with live or dead bacteria proved to prevent plantar edema (p < 0.001). We concluded that Bioflora probiotic given orally or subcutaneously with live or dead bacteria has an anti-inflammatory effect.
Literature
1.
2.
OMahony L, McCarthy J, Kelly P, et al. (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relations to cytokine profiles. Gastroenterology 128(3):541–551CrossRef
3.
Ross RP, Desmond C, Fitzgerald GE, Stanton C (2005) Overcoming the technological hurdles in the development of probiotic foods. J Appl Microbiol 98(6):1410–1417CrossRefPubMed
4.
Laudanno OM, Cesolari JA, Aramberry A y col (2003) Bioflora impidió el sobredesarrollo bacteriano intestinal, en ratas. Actas Cong Arg Gastroent A 80
5.
Urdaci MC, Bressollier P, Pinchuck I.Bacillus clausil probiotic strains- Antimicrobial and immunomodulatory activities. J Clin Gastroent 38:586–590
6.
Means TK, Golenbock DT, Fenton MJ (2000) Structure and function of Toll-like receptor. Life Sci 8 68(3):241–258CrossRef
7.
Rachmilewitz D, Katakura K, Karmeli F, et al. (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126:520–528CrossRefPubMed
8.
Sheil B, McCarthy J, OMahony L, et al. (2004) Is the mucosal route of administration essential for probiotic functions? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53:697–700CrossRef
9.
Laudanno OM, Cesolari JA, Esnarriaga J, et al. (2000) In vivo selectivity of nonsteroidal anti-inflammatory drugs and gastrointestinal ulcers in rats. Dig Dis Sci 45:1359–1365CrossRefPubMed
10.
Kravisg JE, Sharon P, Stenon WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344–1350
11.
Wallace JL, McKnight W, Miyasaka M, et al. (1993) Role of endothelial adhesion molecules in NSAD-induced gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol 265:G993–G998
12.
Jijon H, Baker J, Diaz H, et al. (2004) DNA from probiotic bacteria modulates murine and human epithelial and immune functions. Gastroenterology 126:1358–1373CrossRefPubMed
13.
Alderem A, Ulevitch RJ (2000) Toll-like receptor in induction of the innate immune response. Nature 17:782–787CrossRef
14.
DiGracinto C, Marinaro M, Sanchez M, et al. (2005) Probiotics ameliorate recurrent Th1- mediate murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174:3237–3246
15.
Dunne C, OMahony L, Murphy L, et al. (2001) In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 73(Suppl):3865–3925
16.
Mimura T, Rizzello F, Helwig V, et al. (2004) Once-daily high-dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53:108–114CrossRefPubMed
17.
Kruis W, Fric P, Pokrotnieks J, et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623CrossRefPubMed
18.
Drisko J, Bischoff B, Giles C, et al. (2005) Evaluation of five probiotics for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 50:1113–1117PubMed
19.
Taylor CP, La Mont JT (2005) Genetically engineered probiotic: A new twist on an old remedy. Gastroenterology 128:1509–1512CrossRefPubMed
20.
Mottet C, Michett P (2005) Probiotics: wanted dead or alive. Dig Dis Sci 37:3–6
21.
Reid G, Anand S, Bingham MO, et al. (2005) Probiotic for the developing world. J Clin Gastroent 39:485– 488CrossRefPubMed
Metadata
Title
Anti-Inflammatory Effect of Bioflora Probiotic Administered Orally or Subcutaneously with Live or Dead Bacteria
Authors
OM Laudanno
L Vasconcelos
J Catalana
JA Cesolari
Publication date
01-12-2006
Published in
Digestive Diseases and Sciences / Issue 12/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9175-4

Other articles of this Issue 12/2006

Digestive Diseases and Sciences 12/2006 Go to the issue

ORIGINAL PAPER

Risk of Advanced Proximal Adenoma and Cancer According to Rectosigmoid Findings in the Korean Population

Original Paper

Increased Activity and Expression of Gelatinases in Ischemic Colitis

Original Article

Effects of Intragastric L-Arginine Administration on Proximal Stomach Tone Under Basal Conditions and After an Intragastric Diet

Original Paper

Low Intestinal Glutamine Level and Low Glutaminase Activity in Crohn’s Disease: A Rational for Glutamine Supplementation?

Original Paper

Transepithelial Leak in Barrett’s Esophagus

Letter to the Editor

Is the Time for Absorption and Oxidation of 13C-Octanoate Really Negligible in the Gastric Emptying Breath Test?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits